Health, Health Inequality, and Cost Impacts of Annual Increases in Tobacco Tax: Multistate Life Table Modeling in New Zealand
Using a multistate life table modeling approach, Frederieke van der Deen and colleagues estimate the potential impact of annual increases in tobacco tax on health and health inequalities in New Zealand.
Vyšlo v časopise:
Health, Health Inequality, and Cost Impacts of Annual Increases in Tobacco Tax: Multistate Life Table Modeling in New Zealand. PLoS Med 12(7): e32767. doi:10.1371/journal.pmed.1001856
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1001856
Souhrn
Using a multistate life table modeling approach, Frederieke van der Deen and colleagues estimate the potential impact of annual increases in tobacco tax on health and health inequalities in New Zealand.
Zdroje
1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2224–2260. doi: 10.1016/S0140-6736(12)61766-8 23245609
2. Beaglehole R, Bonita R, Ezzati M, Alleyne G, Dain K, Kishore SP, et al. NCD Countdown 2025: accountability for the 25 x 25 NCD mortality reduction target. Lancet. 2014;384(9938): 105–107. doi: 10.1016/S0140-6736(14)61091-6 25012115
3. IARC. Effectiveness of tax and price policies for tobacco control. IARC handbooks of cancer prevention in tobacco control, Volume 14. Lyon: International Agency for Research on Cancer (IARC); 2011.
4. van Baal P, Meltzer D, Brouwer W. Future costs, fixed healthcare budgets, and the decision rules of cost-effectiveness analysis. Health Econ. 2014; E-pub ahead of print. doi: 10.1002/hec.3138
5. Cobiac LJ, Ikeda T, Nghiem N, Blakely T, Wilson N. Modelling the implications of regular increases in tobacco taxation in the tobacco endgame. Tob control. 2015;24: e154–160 doi: 10.1136/tobaccocontrol-2014-051543 25145342
6. The Parliament of the Commonwealth of Australia. Excise tariff amendment (tobacco) bill 2014. Canberra: The Parliament of the Commonwealth of Australia. http://www.austlii.edu.au/au/legis/cth/bill_em/etab2014276/memo_0.html. Accessed 22 June 2014
7. Hanewinkel R, Isensee B. Five in a row—reactions of smokers to tobacco tax increases: population-based cross-sectional studies in Germany 2001–2006. Tob Control. 2007;16(1): 34–37. 17297071
8. Over EA, Feenstra TL, Hoogenveen RT, Droomers M, Uiters E, van Gelder BM. Tobacco control policies specified according to socioeconomic status: health disparities and cost-effectiveness. Nicotine Tob Res. 2014;16(6): 725–732. doi: 10.1093/ntr/ntt218 24388862
9. Brown T, Platt S, Amos A. Equity impact of population-level interventions and policies to reduce smoking in adults: a systematic review. Drug Alcohol Depend. 2014;138: 7–16. doi: 10.1016/j.drugalcdep.2014.03.001 24674707
10. Brown T, Platt S, Amos A. Equity impact of interventions and policies to reduce smoking in youth: systematic review. Tob Control. 2014; 23:e2 e98–e105
11. Ministry of Social Affairs and Health. Roadmap to a tobacco-free Finland: Action plan on tobacco control. Helsinki: Ministry of Social Affairs and Health; 2014.
12. Department of Health. Tobacco Free Ireland—report of the tobacco policy review group. Dublin: Department of Health; 2013.
13. The Scottish Government. Creating a tobacco-free generation: A tobacco control strategy for Scotland. Edinburgh: The Scottish Government; 2013.
14. World Health Organization Western Pacific Region. Apia communiqué on healthy islands, NCDs and the post-2015 development agenda—tenth pacific health ministers meeting 2013. http://www.wpro.who.int/southpacific/pic_meeting/2013/meeting_outcomes/10th_PHMM_Apia_Commnique.pdf. Accessed 5 May 2015.
15. New Zealand Parliament. Government response to the report of the Māori Affairs Select Committee on its inquiry into the tobacco industry in Aotearoa and the consequences of tobacco use for Māori (final response). Wellington: New Zealand Parliament; 2011.
16. van der Deen FS, Ikeda T, Cobiac L, Wilson N, Blakely T. Projecting future smoking prevalence to 2025 and beyond in New Zealand using smoking prevalence data from the 2013 census. N Z Med J. 2014;127(1406): 71–79. 25447251
17. Tobias M, Blakely T, Matheson D, Rasanathan K, Atkinson J. Changing trends in indigenous inequalities in mortality: lessons from New Zealand. Int J Epidemiol. 2009;38(6): 1711–1722. doi: 10.1093/ije/dyp156 19332501
18. Blakely T, Fawcett J, Hunt D, Wilson N. What is the contribution of smoking and socioeconomic position to ethnic inequalities in mortality in New Zealand? Lancet. 2006;368(9529): 44–52. 16815379
19. Blakely T, Thomson G, Wilson N, Edwards R, Gifford H. The Māori Affairs Select Committee Inquiry and the road to a smokefree Aotearoa. N Z Med J. 2010;123(1326): 7–18. 21326394
20. Edwards R, Hoek J, van der Deen FS. Smokefree 2025—use of mass media in New Zealand lacks alignment with evidence and needs. Aust N Z J Public Health. 2014;38(4): 395–396. doi: 10.1111/1753-6405.12246 24961155
21. Blakely T, Barendregt JJ, Foster RH, Hill S, Atkinson J, Sarfati D, et al. The association of active smoking with multiple cancers: national census-cancer registry cohorts with quantitative bias analysis. CCC. 2013;24: 1243–1255. doi: 10.1007/s10552-013-0204-2 23580085
22. Barendregt J, Oortmarssen GJ, Vos T, Murray CJL. A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr. 2003;1(1): 4. 12773212
23. Ministry of Health. Health Loss in New Zealand: A report from the New Zealand Burden of Diseases, Injuries and Risk Factors Study, 2006–2016. Wellington: Ministry of Health; 2013.
24. Woodward A, Blakely T. The healthy country? A history of life and death in New Zealand. Auckland: University of Auckland Press; 2014.
25. Costilla R, Atkinson J, Blakely T. Incorporating ethnic and deprivation variation to cancer incidence estimates over 2006–2026 for ABC-CBA. Wellington: Department of Public Health, University of Otago, Wellington; 2011.
26. Blakely T, Costilla R, Soeberg M. Cancer excess mortality rates over 2006–2026 for ABC-CBA. Wellington: Department of Public Health, University of Otago, Wellington; 2012.
27. Wilson N, Nghiem N, Foster R, Cobiac L, Blakely T. Estimating the cost of new public health legislation. Bull World Health Organ. 2012;90: 532–539. doi: 10.2471/BLT.11.097584 22807599
28. Ikeda T, Cobiac L, Wilson N, Carter K, Blakely T. What will it take to get to under 5% smoking prevalence by 2025? Modelling in a country with a smokefree goal. Tob Control. 2015;24: 139–145. doi: 10.1136/tobaccocontrol-2013-051196 24072392
29. Verguet S, Gauvreau CL, Mishra S, MacLennan M, Murphy SM, Brouwer ED, et al. The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis. Lancet Glob Health. 2015;3(4): e206–16. doi: 10.1016/S2214-109X(15)70095-1 25772692
30. Grace RC, Kivell BM, Laugesen M. Predicting decreases in smoking with a cigarette purchase task: evidence from an excise tax rise in New Zealand. Tob Control. 2014. doi: 10.1136/tobaccocontrol-2014-051594
31. Ni Mhurchu C, Eyles H, Schilling C, Yang Q, Kaye-Blake W, Genc M, et al. Food prices and consumer demand: differences across income levels and ethnic groups. PLoS ONE. 2013;8(10): e75934. doi: 10.1371/journal.pone.0075934 24098408
32. Hunt D, Blakely T, Woodward A, Wilson N. The smoking-mortality association varies over time and by ethnicity in New Zealand. Int J Epidemiol. 2005;34: 1020–1028. 16030152
33. Thun M, Apicella L, Henley S. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA. 2000;284(6): 706–712. 10927778
34. Hoogenveen R, van Baal P, Boshuizen H, Feenstra T. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. Cost Eff Resour Alloc. 2008;6: 1. doi: 10.1186/1478-7547-6-1 18190684
35. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859): 2129–2143. doi: 10.1016/S0140-6736(12)61680-8 23245605
36. van Baal PHM, Feenstra TL, Polder JJ, Hoogenveen RT, Brouwer WBF. Economic evaluation and the postponement of health care costs. Health Econ. 2011;20(4): 432–445. doi: 10.1002/hec.1599 21210494
37. McLeod M, Blakely T, Kvizhinadze G, Harris R. Why equal treatment is not always equitable: the impact of existing ethnic health inequalities in cost-effectiveness modeling. Popul Health Metr. 2014;12(1): 15.
38. Kivimäki M, Shipley MJ, Ferrie JE, Singh-Manoux A, Batty GD, Chandola T, et al. Best-practice interventions to reduce socioeconomic inequalities of coronary heart disease mortality in UK: a prospective occupational cohort study. Lancet. 2008;372(9650): 1648–1654. doi: 10.1016/S0140-6736(08)61688-8 18994662
39. Capewell S, Graham H. Will Cardiovascular Disease Prevention Widen Health Inequalities? PLoS Med. 2010;7(8): e1000320. doi: 10.1371/journal.pmed.1000320 20811492
40. Gallet CA. Can price get the monkey off our back? A meta-analysis of illicit drug demand. Health economics. 2014;23(1): 55–68. doi: 10.1002/hec.2902 23303721
41. Wilson N, Edwards R, Parry R. A persisting secondhand smoke hazard in urban public places: results from fine particulate (PM2.5) air sampling. N Z Med J. 2011;124(1330): 34–47. 21681251
42. Thomson G, Wilson N, Bushell L, Al Matar W, Ball B, Chiu J, et al. Butt lengths differ by area deprivation level: a field study to explore intensive smoking. Nicotine Tob Res. 2008;10(5): 927–931. doi: 10.1080/14622200802027222 18569769
43. Grace RC, Kivell BM, Laugesen M. Estimating cross-price elasticity of e-cigarettes using a simulated demand procedure. Nicotine Tob Res. 2015;17(5): 592–598. doi: 10.1093/ntr/ntu268 25548256
44. Jimenez S, Labeaga JM. Is it possible to reduce tobacco consumption via alcohol taxation? Health Econ. 1994;3(4): 231–241. 7994323
45. Lee JM, Chen MG, Hwang TC, Yeh CY. Effect of cigarette taxes on the consumption of cigarettes, alcohol, tea and coffee in Taiwan. Public Health. 2010;124(8): 429–436. doi: 10.1016/j.puhe.2010.04.008 20655077
46. Young-Wolff KC, Kasza KA, Hyland AJ, McKee SA. Increased cigarette tax is associated with reductions in alcohol consumption in a longitudinal U.S. sample. Alcohol Clin Exp Res. 2014;38(1): 241–248. doi: 10.1111/acer.12226 23930623
47. Wilson N, Thomson G, Tobias M, Blakely T. How much downside? Quantifying the relative harm from tobacco taxation. J Epidemiol Comm Health. 2004;58(6): 451–454.
48. Bala MM, Strzeszynski L, Topor-Madry R, Cahill K. Mass media interventions for smoking cessation in adults. Cochrane Database Syst Rev 6. 2013;6: CD004704.
49. Donny EC, Hatsukami DK, Benowitz NL, Sved AF, Tidey JW, Cassidy RN. Reduced nicotine product standards for combustible tobacco: Building an empirical basis for effective regulation. Prev Med. 2014;67: 17–22.
50. Pearson AL, van der Deen FS, Wilson N, Cobiac L, Blakely T. Theoretical impacts of a range of major tobacco retail outlet reduction interventions: modelling results in a country with a smokefree nation goal. Tob Control. 2014;24: e32–338. doi: 10.1136/tobaccocontrol-2013-051362 25037156
51. Warner KE. An endgame for tobacco? Tob Control. 2013;22: i3–i5. doi: 10.1136/tobaccocontrol-2013-050989 23591502
52. Nghiem N, Blakely T, Cobiac L, Pearson A, Wilson N. Health and economic impacts of eight different dietary salt reduction interventions. PLoS ONE. 2015;10(4): e0123915. doi: 10.1371/journal.pone.0123915 25910259
53. Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014;32: 2645–2656. doi: 10.1016/j.vaccine.2014.02.071 24662710
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2015 Číslo 7
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Ebola Virus Disease: Experience and Decision Making for the First Patients outside of Africa
- Searching for Public Health Law’s Sweet Spot: The Regulation of Sugar-Sweetened Beverages
- Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study
- Individual Participant Data (IPD) Meta-analyses of Randomised Controlled Trials: Guidance on Their Use